title: [Eradication rate of first-line and second-line therapy for Helicobacter pylori infection, and reinfection rate after successful eradication].
abstract: OBJECTIVE
  The increasing trend of antibiotic resistance emphasizes the need for the assessment of eradication rate of first and second-line therapy for Helicobacter pylori (H. pylori) infection. The reinfection rate depends on the geographical, national, or socioeconomic status of the patients. The aim of this study was to evaluate the recent 5-year changes of eradication rates and the reinfection rates after the successful eradication of Helicobacter pylori infection for 3-years follow-up in Bucheon, Korea.
  
  
  METHODS
  From February 2001 to August 2006, 3,267 patients with H. pylori-positive peptic ulcer disease received the first-line therapy for 7 days. The 317 patients who failed to the first-line therapy received the second-line therapy for 7 days. The 167 patients with 3-years follow-up after the successful eradication were included. 13C-urea breath tests or rapid urease tests and histologies were assessed to determine the H. pylori status after the eradication.
  
  
  RESULTS
  The eradication rate of first-line therapy was 83.7% in 2001, 83.4% in 2002, 83.7% in 2003, 85.9% in 2004, 87.2% in 2005, and 81.8% in 2006 by per protocol analysis (PP), respectively. The eradication rate of second-line therapy was 80.0% in 2002, 86.8% in 2003, 89.7% in 2004, 98.0% in 2005, and 78.8% in 2006 by PP. The cumulative reinfection rate was 6.0%. The annual reinfection rate was 2.0%. The recurrence rate of peptic ulcer was 17.2% in the patients without reinfection and 50% with reinfection.
  
  
  CONCLUSIONS
  The eradication rate for H. pylori have not changed in the recent 5-years. The annual reinfection rate was low. The successful eradication of H. pylori was effective for preventing the recurrence of peptic ulcers.
authors: Department of Internal Medicine, Institute for Digestive Research, Soonchunhyang University School of Medicine, Bucheon and Seoul, Korea.
authors: Hyun Sik
authors: HS
authors: Na
authors: Su Jin
authors: SJ
authors: Hong
authors: Hyo Joong
authors: HJ
authors: Yoon
authors: Joo Hee
authors: JH
authors: Maeng
authors: Bong Min
authors: BM
authors: Ko
authors: In Sup
authors: IS
authors: Jung
authors: Chang Beom
authors: CB
authors: Ryu
authors: Jin Oh
authors: JO
authors: Kim
authors: Joo Young
authors: JY
authors: Cho
authors: Joon Seong
authors: JS
authors: Lee
authors: Moon Sung
authors: MS
authors: Lee
authors: Chan Sup
authors: CS
authors: Shim
authors: Boo Sung
authors: BS
authors: Kim
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003710:Demography; D005260:Female; D005500:Follow-Up Studies; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000517:prevention & control; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000382:microbiology / Q000628:therapy; D012008:Recurrence; D012074:Remission Induction; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents